Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab.
B cells
CD4+ T cells
CD8+ T cells
SARS-CoV-2
antibodies
mRNA vaccine
multiple sclerosis
ocrelizumab
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
07
2023
accepted:
30
08
2023
medline:
23
10
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
Since the development of the coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there has been significant interest in determining the effectiveness of SARS-CoV-2 vaccines in patients under immunomodulatory or immunosuppressive therapies. The aim of this study was to evaluate the impact of ocrelizumab, a monoclonal anti-CD20 antibody, on SARS-CoV-2-specific T cell and B cell responses in patients with relapsing-remitting multiple sclerosis (RRMS). To this end, peripheral blood mononuclear cells (PBMCs) were isolated from Our data indicate a significant difference in the SARS-CoV-2 specific IFN-γ ( Our results call for a critical discussion regarding appropriate vaccination intervals and potential biomarkers for the prediction of (re)infection with SARS-CoV-2 in patients with MS receiving ocrelizumab. DRKS00029110; URL: http://apps.who.int/trialsearch/.
Identifiants
pubmed: 37841269
doi: 10.3389/fimmu.2023.1254128
pmc: PMC10569464
doi:
Substances chimiques
ocrelizumab
A10SJL62JY
spike protein, SARS-CoV-2
0
COVID-19 Vaccines
0
Antibodies, Monoclonal, Humanized
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1254128Informations de copyright
Copyright © 2023 Groß-Albenhausen, Weier, Velten, Heider, Chunder and Kuerten.
Déclaration de conflit d'intérêts
Author RC received funding from the Deutsche Forschungsgemeinschaft DFG, German Research Foundation under Germany’s Excellence Strategy – EXC2151 – 390873048. Author SK reports funding from the DFG, Novartis, F. Hoffmann-La Roche and Sanofi; and speaker fees and consultancy honoraria from Novartis, F. Hoffmann-La Roche, Sanofi, and Teva outside the submitted work. Author SK is also supported by the DFG IRTG 2168, grant no. 272482170 and is a member of the Excellence Cluster “ImmunoSensation2” EXC2151 – 390873048. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mult Scler. 2022 Jun;28(7):1041-1050
pubmed: 35575234
Neurology. 2022 Feb 1;98(5):e541-e554
pubmed: 34810244
Brain. 2019 Jan 1;142(1):120-132
pubmed: 30561509
JAMA Neurol. 2021 Dec 1;78(12):1510-1514
pubmed: 34554197
Sci Rep. 2021 Oct 15;11(1):20499
pubmed: 34654826
Methods Mol Biol. 2012;792:3-23
pubmed: 21956497
Clin Immunol. 2007 Sep;124(3):267-76
pubmed: 17632036
Nature. 2020 Dec;588(7838):498-502
pubmed: 32805734
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Brain. 2018 Jul 1;141(7):2066-2082
pubmed: 29873694
Front Immunol. 2022 Apr 27;13:867189
pubmed: 35572552
Eur J Neurol. 2015 Oct;22 Suppl 2:3-13
pubmed: 26374508
Methods Mol Biol. 2012;792:155-71
pubmed: 21956509
Mult Scler Relat Disord. 2020 Oct;45:102439
pubmed: 32769063
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
Expert Rev Vaccines. 2009 Jun;8(6):779-89
pubmed: 19485757
Cell Rep. 2021 Aug 24;36(8):109591
pubmed: 34433030
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835
pubmed: 34035836
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Inflamm Res. 2022 Nov;71(10-11):1181-1189
pubmed: 35951029
Arthritis Rheum. 2009 Dec;60(12):3563-71
pubmed: 19950291
Nat Rev Immunol. 2015 Sep 15;15(9):545-58
pubmed: 26250739
Neurol Sci. 2022 Mar;43(3):1557-1567
pubmed: 35006442
Front Immunol. 2021 Dec 09;12:781843
pubmed: 34956211
Neurology. 2014 Sep 9;83(11):1022-4
pubmed: 25200713
Mult Scler Relat Disord. 2022 Nov;67:104079
pubmed: 35952457
Nat Rev Immunol. 2002 Jun;2(6):401-9
pubmed: 12093006
J Proteins Proteom. 2021;12(2):81-91
pubmed: 33850392
Neurology. 2019 Mar 5;92(10):469-480
pubmed: 30770422
Anal Bioanal Chem. 2021 May;413(13):3501-3510
pubmed: 33768365
Nat Rev Drug Discov. 2021 Mar;20(3):179-199
pubmed: 33324003
Cell. 2020 Nov 25;183(5):1340-1353.e16
pubmed: 33096020
Front Immunol. 2022 Jan 17;12:796482
pubmed: 35111162
Ann Rheum Dis. 2021 Oct;80(10):1322-1329
pubmed: 34362747
Expert Rev Vaccines. 2011 Mar;10(3):299-306
pubmed: 21434798
Mult Scler J Exp Transl Clin. 2023 Apr 5;9(2):20552173231165196
pubmed: 37057191
JAMA Netw Open. 2022 May 2;5(5):e2211497
pubmed: 35544139
Nat Immunol. 2021 May;22(5):620-626
pubmed: 33674800
EBioMedicine. 2021 Oct;72:103581
pubmed: 34563483
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
Ann Neurol. 2022 Jan;91(1):89-100
pubmed: 34687063
Cells. 2012 May 10;1(2):111-26
pubmed: 24710418
Front Immunol. 2022 Aug 05;13:926318
pubmed: 35990701
Eur J Neurol. 2023 Aug;30(8):2357-2364
pubmed: 37154406
J Clin Med. 2022 Nov 21;11(22):
pubmed: 36431332
J Immunol Methods. 1983 Dec 16;65(1-2):109-21
pubmed: 6361139
Mult Scler Relat Disord. 2022 Apr;60:103719
pubmed: 35276450
Methods. 2012 Jul;57(3):383-91
pubmed: 22251671
Front Immunol. 2017 Sep 20;8:1160
pubmed: 28979263
J Immunol Methods. 2013 Aug 30;394(1-2):84-93
pubmed: 23707324
Mult Scler Relat Disord. 2022 Jan;57:103382
pubmed: 35158475
Neurol Neuroimmunol Neuroinflamm. 2021 Mar 11;8(3):
pubmed: 33707177
Ann Neurol. 2022 Jun;91(6):782-795
pubmed: 35289960
J Immunol Methods. 2023 Apr;515:113443
pubmed: 36842524
Ann Neurol. 2018 Jan;83(1):13-26
pubmed: 29244240
Sci Immunol. 2020 Dec 22;5(54):
pubmed: 33443036
Front Immunol. 2022 Oct 26;13:1025377
pubmed: 36389698
Nat Rev Neurol. 2021 Dec;17(12):729-730
pubmed: 34686837
Cells. 2021 Jan 27;10(2):
pubmed: 33514016
Sci Transl Med. 2014 Aug 6;6(248):248ra107
pubmed: 25100741
Ann Neurol. 2021 Nov;90(5):834-839
pubmed: 34516013
Clin Microbiol Infect. 2021 Jul;27(7):1029-1034
pubmed: 33813122
Methods Mol Biol. 2015;1312:427-34
pubmed: 26044024
Mult Scler Relat Disord. 2023 Feb;70:104484
pubmed: 36608538
J Neurol. 2022 Apr;269(4):2259-2261
pubmed: 35286479
Cell Immunol. 1989 Apr 15;120(1):205-17
pubmed: 2539266
Mult Scler Relat Disord. 2022 Mar;59:103560
pubmed: 35093840
N Engl J Med. 2017 Jan 19;376(3):209-220
pubmed: 28002688
Proc Natl Acad Sci U S A. 2019 Dec 17;116(51):25800-25807
pubmed: 31748274
BMC Microbiol. 2021 Feb 22;21(1):58
pubmed: 33618668
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
N Engl J Med. 2017 Jan 19;376(3):221-234
pubmed: 28002679
Mult Scler. 2023 May;29(6):648-656
pubmed: 36440826
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Nature. 1985 Apr 11-17;314(6011):537-9
pubmed: 3157869
Rev Neurol (Paris). 2021 Dec;177(10):1237-1240
pubmed: 34172292
Methods Mol Biol. 2015;1312:419-26
pubmed: 26044023
Neurol Res Pract. 2021 Nov 22;3(1):60
pubmed: 34802469
Nat Rev Immunol. 2022 Dec;22(12):734-750
pubmed: 35508809
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
Vaccines (Basel). 2018 Jul 21;6(3):
pubmed: 30037078
JAMA Neurol. 2020 Feb 1;77(2):184-191
pubmed: 31589278
Front Immunol. 2022 Aug 30;13:988536
pubmed: 36110861